Sign up to save your podcasts
Or
Share CAR T-cell therapy
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
CAR T-cell therapy
Frederick Locke joins The Lancet Oncology to discuss long-term results from the ZUMA-1 trial on the safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
View all episodes
By The Lancet Group
5
11 ratings
Frederick Locke joins The Lancet Oncology to discuss long-term results from the ZUMA-1 trial on the safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Tell us what you thought about this episode
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
More shows like The Lancet Oncology in conversation with
View all
Nature Podcast
758 Listeners
Science Magazine Podcast
811 Listeners
JAMA Editors' Summary
131 Listeners
NEJM This Week
325 Listeners
Journal of Clinical Oncology (JCO) Podcast
38 Listeners
JAMA Clinical Reviews
496 Listeners
ASCO Daily News
58 Listeners
JAMA Medical News
90 Listeners
Core IM | Internal Medicine Podcast
1,095 Listeners
ASCO Guidelines
43 Listeners
The Readout Loud
318 Listeners
Annals On Call Podcast
194 Listeners
Think Fast Talk Smart: Communication Techniques
799 Listeners
The Lancet Voice
23 Listeners
The Lancet Child & Adolescent Health in conversation with
0 Listeners
The Lancet Digital Health in conversation with
0 Listeners
The Lancet Global Health in conversation with
2 Listeners
The Lancet Psychiatry in conversation with
0 Listeners
The Lancet Respiratory Medicine in conversation with
2 Listeners
The Lancet in conversation with
1 Listeners
The Lancet Haematology in conversation with
0 Listeners
The Lancet Gastroenterology & Hepatology in conversation with
0 Listeners
The Lancet Diabetes & Endocrinology in conversation with
1 Listeners
The Lancet Infectious Diseases in conversation with
0 Listeners
The Lancet Healthy Longevity in conversation with
0 Listeners
The Lancet Public Health in conversation with
1 Listeners
The Lancet Microbe in conversation with
0 Listeners
In conversation with...
0 Listeners
eBioMedicine in conversation with
0 Listeners
eClinicalMedicine in conversation with
0 Listeners
The Lancet Rheumatology in conversation with
0 Listeners
Two Onc Docs
169 Listeners
The Lancet Regional Health in conversation with
0 Listeners